Related Experiment Videos
Lysosomal acid lipase and atherosclerosis
1The Children's Hospital Research Foundation of Cincinnati Children's Hospital Medical Center, and the Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio 45229-3039, USA.
Current Opinion in Lipidology
|September 14, 2004
Summary
Enzyme therapy using human lysosomal acid lipase effectively reduced atherosclerotic lesions in mice. This treatment targets macrophages and the liver, offering a novel approach to combat atherosclerosis.
Area of Science:
- Cardiovascular Research
- Enzyme Therapy
- Atherosclerosis Pathogenesis
Background:
- Atherosclerosis is a primary cause of mortality globally.
- Current treatments include statins, diet, and exercise, but novel strategies are needed.
- Lysosomal acid lipase (LAL) plays a role in lipid metabolism.
Purpose of the Study:
- To investigate the therapeutic potential of LAL enzyme therapy.
- To evaluate LAL's effect on atherosclerotic lesions in a mouse model.
- To elucidate the molecular mechanisms underlying LAL's efficacy.
Main Methods:
- Administration of human LAL via tail vein injection in atherosclerotic mice.
- Assessment of aortic and coronary ostial lesions.
- Analysis of lesional composition (macrophages, collagen, necrosis).
- Measurement of plasma and hepatic lipid levels (cholesteryl esters, triglycerides).
Main Results:
- LAL treatment eliminated early atherosclerotic lesions and reduced advanced lesion size.
- Lesion reduction correlated with decreased foamy macrophages, collagen, and necrotic areas.
- LAL-treated mice showed reduced plasma cholesteryl esters and hepatic cholesterol/triglycerides.
Conclusions:
- Administered LAL impacts atherogenesis through direct action on lesional macrophages.
- LAL also exerts systemic effects, reducing hepatic lipid release and potentially VLDL/LDL production.
- LAL enzyme therapy presents a promising strategy for treating atherosclerosis.